Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tenaya Therapeutics ( (TNYA) ) just unveiled an announcement.
Tenaya Therapeutics announced that board member David Goeddel submitted his resignation from the company’s board of directors and all board committees on December 31, 2025, with the resignation to take effect on January 26, 2026, in connection with his retirement. The company emphasized that Goeddel’s departure was voluntary, not due to any disagreement over operations, policies or practices, and the board publicly thanked him for his service and contributions, signaling an orderly leadership transition rather than a governance dispute.
The most recent analyst rating on (TNYA) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Tenaya Therapeutics stock, see the TNYA Stock Forecast page.
Spark’s Take on TNYA Stock
According to Spark, TipRanks’ AI Analyst, TNYA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large losses, and heavy cash burn with ongoing funding needs) and bearish technicals (price below key moving averages with negative MACD). A positive regulatory and clinical update provides some upside support, but it is not yet enough to offset the financial and trend risks.
To see Spark’s full report on TNYA stock, click here.
More about Tenaya Therapeutics
Tenaya Therapeutics, Inc. is a biotechnology company operating in the life sciences industry, overseen by a board of directors that includes independent scientific and industry leaders who help guide the company’s strategic and operational decisions.
Average Trading Volume: 5,121,766
Technical Sentiment Signal: Sell
Current Market Cap: $154M
See more data about TNYA stock on TipRanks’ Stock Analysis page.